Abstract
Over 110 million units of blood are collected yearly. The need for blood products is greater in developing countries, but so is the risk of contracting a transfusion-transmitted infection. Without efficient donor screening/viral testing and validated pathogen inactivation technology, the risk of transfusion-transmitted infections correlates with the infection rate of the donor population. The World Health Organization has published guidelines on good manufacturing practices in an effort to ensure a strong global standard of transfusion and blood product safety. Sub-Saharan Africa is a high-risk region for malaria, human immunodeficiency virus (HIV), hepatitis B virus and syphilis. Southeast Asia experiences high rates of hepatitis C virus. Areas with a tropical climate have an increased risk of Zika virus, Dengue virus, West Nile virus and Chikungunya, and impoverished countries face economical limitations which hinder efforts to acquire the most modern pathogen inactivation technology. These systems include Mirasol® Pathogen Reduction Technology, INTERCEPT®, and THERAFLEX®. Their procedures use a chemical and ultraviolet or visible light for pathogen inactivation and significantly decrease the threat of pathogen transmission in plasma and platelets. They are licensed for use in Europe and are used in several other countries. The current interest in the blood industry is the development of pathogen inactivation technologies that can treat whole blood (WB) and red blood cell (RBC). The Mirasol system has recently undergone phase III clinical trials for treating WB in Ghana and has demonstrated some efficacy toward malaria inactivation and low risk of adverse effects. A 2nd-generation of the INTERCEPT® S-303 system for WB is currently undergoing a phase III clinical trial. Both methodologies are applicable for WB and components derived from virally reduced WB or RBC.
Keywords: blood, red blood cell, virus, pathogen, inactivation
Introduction
Each year, over 110 million units of blood donations are collected worldwide. Nearly half of these donations come from developed countries that are home to less than 20% of the global population. In high-income countries, products from transfusion, including red blood cells (RBC), platelets and plasma, are most commonly used in aiding cardiovascular and transplant surgery, and to provide therapeutic support in heavy trauma and haematologic malignancies. In lower income countries, blood transfusions are used more frequently in managing malaria, anaemia, trauma and pregnancy-related complications. Each unit of blood has the potential to benefit several types of pathologies, but each infected or contaminated blood product can severely harm its recipients1. In the absence of efficient and cost effective donor screening, viral testing and pathogen inactivation, the risk-benefit ratio of the blood products is directly dependent on the infection rate of the donor population2.
Although generally following international guidelines and guides, different countries can tailor their specific donor selection criteria and process guidelines based on their own epidemiological and economical standards. As a result, risk levels vary between countries. For example, in Italy, transfusion recipients face an estimated residual risk of 1 in 72,000 for hepatitis B virus (HBV) after blood screening by nucleic acid testing (NAT), whereas in Germany the respective remaining risk is approximately 1 in 620,0003. For hepatitis C virus (HCV), in Italy, it is approximately 1 in 5,000,000 as compared to approximately 1 in 1,150,000 in the USA3. The risk of receiving a human immunodeficiency virus (HIV)-infected blood product in Spain is almost 7 times more likely than in Germany2 and over 14 times more likely than in Canada3. Malaria is prevalent in sub-Saharan Africa. In Ghana, the blood recipient and donor prevalence for being parasitemic for at least one of four species of plasmodium is over 50%4.
Fortunately, current pathogen inactivation technologies (PITs) are effective against parasites, including plasmodium. In an effort to maintain a global standard, the World Health Organization (WHO) published a set of guidelines on good manufacturing practices to regulate the collection and processing of blood products in 20115. Since then, there have been major developments regarding donor screening, blood processing, testing and storage procedures. Because of the great demand for access to quality blood products, a number of safety nets have been set in place to minimise the contamination of blood products by viruses, and adventitious bacteria, parasites or other harmful agents. These include strict donor selection and screening procedures, and blood handling protocols, but these do not completely eradicate the threat of unwanted pathogens. Some countries have begun implementing new forms of PIT to lessen the occurrence of disease transmission by transfusion. There has been remarkable progress in the safety of transfusions over the past few decades due to new measures targeting infectious threats. The continued development of new pathogen safety strategies is critical as new viruses emerge and the demand for transfusions continues. In the United Kingdom, there were major problems with the risk of prion transmission through transfusion. This led to the development of a prion removal filter.
Relevant blood-borne pathogens, and relative degree of risks
HIV, HBV, HCV, and to a lesser extent West Nile virus (WNV), Zika virus (ZIKV) and Dengue virus (DENV), are among several viruses potentially associated with blood transfusions and are targeted for removal by testing and/or inactivation. Syphilis is still a significant bacterial blood-borne target in developing countries, though not as much in developed countries, and plasmodium is a major parasite monitored for removal6.
HIV I and II
The HIV/AIDS pandemic is among the greatest health challenges in modern history7. HIV-1 progresses faster and is more transmissible than HIV-28. The combination of a large regional demand for blood products, inadequate testing of blood products, and the extremely high (95–100%) efficiency of HIV transmission through unsafe blood products contribute to the high risk of transfusion-associated HIV9. In addition, HIV is one of several viruses that can infect multiple cellular and plasma components of blood products6. An analysis testing HIV-positive blood samples conducted with relatively modern amplification procedures and sequencing techniques demonstrated that HIV viral sequences could be found in 99% of peripheral blood mononuclear cells (PBMNC). HIV-infected plasma samples were shown to be negative for HIV RNA sequences. However, HIV-1 RNA was present in over 85% of the samples10. This is consistent with a previous study which indicated that HIV RNA is highly associated with PBMNCs, plasma and platelets11.
HBV
Data on the seroprevalence of HBV are limited for many developing countries12. The WHO reported that approximately 240 million people live with chronic hepatitis B13. HBV is primarily spread through mucosal exposure to infected blood or body fluids. Once infected, the subject may clear the infection and develop immunity or become a chronic carrier and be at risk of developing liver cirrhosis or hepatocellular carcinoma12. To lower the risk of HBV transfusion transmission, donor blood is screened for hepatitis B surface antigen (HBsAg) and, in some countries, anti-hepatitis B core (HBc) antibodies14. HBV can be found in approximately 0.03% of blood donations in high-income countries, as compared to close to 0.1% in mid-income countries and 3.7% in some countries of lower income15. Interestingly, HBV had the highest prevalence of all transfusion-transmittable diseases in Australia in 2014 and previous years16. HBV can be transmitted by non-virally inactivated plasma components and cellular blood components6. Seed et al. determined the statistical transmission rate of donor blood components from patients with occult HBV infections (OBI), defined as having anti-HBc reactivity as well as low quantities of HBV DNA and without traceable HBsAg, and patients who tested “inconclusive” (donor individuals with anti-HBs <100 IU/I) for HBV. The combined results showed an anti-HBc rate of 2.86% in RBC, 3.01% in plasma components, and HBV was completely absent (0%) in cryoprecipitate or platelets17. As with other viruses, the possibility of HBV being hidden in a window-period increases the challenge in detecting it during screening processes.
HCV
Hepatitis C virus is a member of the family Flaviviridae18. Between 170 and 184 million people (2–3% of the global population) are infected with HCV18–20. Most HCV cases become chronic, potentially leading to progressive liver cirrhosis, fibrosis and liver cancer18,21. There are at least 6 major genotypes of HCV which can be further divided into 83 subgroups22. HVC-1 can be found globally, including Europe and North America18,23. The wide distribution of HCV-1 is, in part, the result of blood transfusions and needle sharing, such as among drug addicts18. In West Africa, HCV infections are predominantly caused by HCV-2, whereas HCV-1 and HCV-4 are more common in central Africa, sub-Saharan Africa, with HCV-4 having a heavy presence in Egypt21. HVC-3 and HCV-6 is often identified in South-East Asia and India, and HCV-5 is common only in South Africa18. The spread of HCV by blood transfusion used to be common in the USA, but became rare once anti-HCV screening became available in 199224. Similarly to HBV, HCV may be transmitted through blood transfusion in cellular blood components as well as plasma products6. Although HCV can enter cells through the CD81 receptor, which is absent in platelets, according to an in vitro study using HCV-negative blood, HCV can infect platelets through alternative means25. However, HCV-RNA levels are higher in serum compared to platelets26. A study ranking the general distribution of HCV-RNA in infected blood components found whole blood to have the highest amount of HCV-RNA and significantly more than in plasma, which was significantly more than in PBMC, which was more than in neutrophils, which contained the least amount of HCV-RNA27. Although screening criteria are in place to prevent transfusion transmission, HCV can have a window period of roughly two months, making it extremely difficult to detect by anti-HCV antibody screening at early stages of infection28, and justifying efforts to introduce NAT.
WNV
In addition to ZIKV and DENV, WNV is also a flavivirus transmitted by Aedes mosquitos. A major difference is that the primary hosts of WNV are birds. Although WNV can also infect humans and other vertebrates, the amount of virus required to cause successful transmission is unknown29. WNV has infected over 1 million people in the USA. While WNV is generally asymptomatic, it is the greatest cause of viral encephalitis in the USA30, despite the fact that less than 1% of those infected with WNV develop neurodegenerative diseases31. More common symptoms of WNV include fever, headaches, chills and fatigue32. WNV has been demonstrated to bind to circulating RBC and is transmissible through blood transfusion29. The detection of WNV culture-positive plasma suggests the potential for fresh frozen plasma (FFP) to also be a means of transmission of WNV32.
DENV
Similarly to ZIKV, DENV is a flavivirus transmitted by the Aedes mosquitos. There are 4 serotypes of the virus (DEN-1 – DEN-4). DENV presents a broad spectrum of symptoms ranging from asymptomatic to fatal33. A large proportion of infections, as much as 87%, do not advance to a clinical stage34. However, the clinical symptoms can cause dengue fever, haemorrhagic fever, or febrile illness. There have been reports of DENV outbreaks in many of the same regions where Zika virus is present. The spread of DENV, in combination with the high dangers associated among a proportion of those infected, has led to an increased concern for DENV transmission via blood products. Studies have indicated that DENV can bind to human platelets in the presence of virus-specific antibody35 as well as replicate in peripheral blood mononuclear cells36. DENV is known to associate with blood components as well as plasma products6.
Chikungunya virus
As is the case with many viruses in tropical regions, the primary method of transmission of chikungunya virus (CHIKV) is through various Aedes mosquitos37. First identified in Africa in the 1950s, reports of CHIKV transmission through transfusion have so far been rare38. However, over the past decade, significant outbreaks of a mutated form of CHIKV have occurred in islands in the Indian Ocean, in the Caribbean and in Europe, in large part due to tourism and international shipping around the world37–39. CHIKV is an RNA-enveloped virus that produces symptoms including rash, fever, and arteritis37. Severe cases can cause uveitis, dendritic lesions, and various forms of neuritis40,41.
ZIKV
ZIKV, an arthropod-borne flavivirus primarily transmitted by the Aedes mosquitos, induces temporary, mild symptoms including rash, headaches and fever in infected individuals42,43, but is often transmitted without producing symptoms, leaving infected individuals unaware of their condition. Seemingly healthy pregnant mothers have reported more serious fetal abnormalities, including intrauterine growth restrictions and microcephaly, as well as pregnancy complications including miscarriages and stillborn deliveries42–44. Zika outbreaks have been recorded in Africa, North and South America, and Asia43. In 2013–2014, French Polynesia experienced the largest Zika outbreak to date45. During that outbreak, almost 3% of blood donors were shown to be positive for ZIKV46. The recent ZIKV epidemic has led to many new concerns over transfusion safety. The impact of ZIKV on blood products is still under investigation by the WHO. However, recent reports indicate platelet transfusion as a means of transmission for ZIKV47. The FDA now recommends testing blood components of all donated blood in the USA for ZIKV48.
Syphilis
Also nicknamed “the great imitator” and “the great pox”, syphilis is a disease caused by the spirochetal bacterium Treponema pallidum49. Syphilis progresses through 3 lifelong stages, which ultimately lead to breakdown of the nervous system and heart failure50. Primary syphilis typically occurs within the first three months after exposure with symptoms such as painless lesions and chancres in the external genital regions, hands or lips. Secondary syphilis often occurs 2–8 weeks after the disappearance of primary symptoms, but occasionally primary symptoms remain. Secondary syphilis symptoms include fever, rash, headaches and pharyngitis. Tertiary syphilis has become far more rare as a result of modern antibiotics, but symptoms include cellular necrosis, fibrosis, and neurological and cardiovascular problems49. Syphilis is mostly transmitted sexually, but can also be transmitted congenitally, or rarely as a result of transfusion51–53. Pregnancy complications occurring as a result of syphilis include stillbirths, miscarriages and newborns with congenital syphilis. Despite recent increases in syphilis cases in the USA, syphilis is a greater problem for the developing world49,51. This is a cause for concern with regard to the generation of blood products. According to a study carried out in Burkina Faso, the seroprevalence of syphilis among first time blood donors is approximately 1.5%54. Syphilis can be associated with transfusion transmission through cellular component-based products, but not plasma products6.
Malaria
Malaria is believed to be the most important parasitic disease currently facing humans55. In 2015, 95 countries and territories had active cases of malaria transmission. Today, approximately 3.2 billion people, or half the world’s population, is at risk for malaria. Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae are protozoans responsible for the disease known as malaria56. Plasmodium falciparum is the main parasite associated with severe clinical malaria and is the most fatal of the malaria plasmodia55. Malaria is typically transmitted to humans by the female anopheline mosquito during bloodmeal57. In sub-Saharan Africa, Malaria infects approximately 150 million people and leads to between 660,000 and 3 million deaths annually55,58,59. The first symptoms include vomiting, chills, headache and fever59. If not treated immediately, the disease may progress to severe anaemia, respiratory distress, impaired consciousness, abnormal bleeding and cerebral malaria55,60. Currently, it is estimated that only 10% of global malaria cases are detected59. Malaria infection involves the plasmodium invading RBC61. Individuals with sickle cell anaemia tend to be less susceptible to the effects of malaria due to the structure of their erythrocytes, making it difficult for malaria replication. Due to a combination of malaria prevalence, inefficient methods of blood screening, limited resources, and the speed at which blood products are received and transfused, there is a persistent risk of transfusion-transmitted malaria in sub-Saharan Africa. Unfortunately, routine serological tests that are typically effective at limiting the risk of transmission of HIV, HBV, HCV and syphilis are not as successful against malaria53. PIT to inactivate plasmodium in whole and red blood cells exists, but is not yet commercially available62.
Prions
Infectious improperly-folded proteins known as prions are capable of producing infection. The free or cell-bound form of prions can contribute to a number of serious diseases. Among them are kuru, Gerstmann-Straüssler-Scheinker syndrome, fatal familial insomnia and transmissible spongiform encephalopathy (called Creutzfeldt-Jakob disease [CJD]), which is an untreatable, potentially fatal neurodegenerative disease63. Since the first reported iatrogenic transmission of CJD in 1972, there have been 4 documented cases of individuals acquiring the variant form of CJD (vCJD) from non-leucocyte reduced red cells64. A filter containing an affinity resin capable of adsorbing prions from RBC concentrate has had CE marking since 2006. The decision as to whether to require prion removal as part of screening procedures on collected RBC in the United Kingdom is still pending. (The issue is under the scrutiny of the advisory committee on the safety of blood, tissues and organs [SaBTO]).
Transfusion-transmitted sepsis
While blood-borne infections are a critical concern for blood transfusion safety, transfusion-transmitted sepsis is a less, but still significant, concern occurring in approximately 1 out of every 2,000–3,000 transfusions according to the CDC65. The most frequent contaminant of blood for transfusion is the gram-positive skin-borne bacteria called Staphylococcus aureus. Contamination typically occurs as a result of the skin surface not being properly cleaned and bacteria from the skin passing into the donated blood through the collection needle65. This is the most common cause of bacterial contamination of platelets66. Gram-negative bacteria such as Escherichia coli (E. coli), Acineobacter and Klebsiella can be present in blood donations from symptomless donors and cause infections such as pneumonia, meningitis or other severe illnesses in blood recipients65. In addition, Staphylococcus aureus and Bacillus cereus are largely implicated in the contamination of contamination of platelets. Platelets in plasma stored at room temperature provide an ideal media for bacterial growth66.
Other emerging pathogens
In addition to the well-established pathogens mentioned above, it is critical to consider the threat of emerging pathogens when discussing the risks of transfusion-transmission infections. Among newly emerging pathogens is the Ross River virus (RRV), in which the first reported transfusion-transmitted case was confirmed by the Australian Red Cross on May of 201467. The patient had received RBC from a donor who was subsequently diagnosed with RRV less than a week after donating blood. Other new TTI threats include babesia, which are intraerythrocytic protozoan parasites more commonly transmitted by tick when humans are accidental hosts. Although many people infected with babesia do not develop symptoms, babesia can be life-threatening for the elderly or those with weakened immune systems. Chagas disease, produced by a protozoan parasite called Trypanosoma cruzi is another parasite typically transmitted to humans by insect. The pathogen for Chagas disease can exist freely in blood and consequently can be transmitted via blood transfusion. Chagas disease can produce severe cardiac and gastrointestinal dysfunction. It is difficult to assess individual risks for the many TTIs because many of them depend on a number of factors that have not been fully established and/or that vary from country to country68.
Methods of pathogen inactivation licensed or under development for cellular components and plasma for transfusion
Historically, the first blood products to have successfully been subjected to efficient viral inactivation treatments are the fractionated plasma derivatives69. In efforts to heighten safety, improve blood product quality, and decrease the rate of TTIs, various technologies have subsequently been designed to inactivate pathogens also in blood components and supplement the existing donor screening and donation testing processes. Pathogen inactivation (PI) refers to technology that applies a physical, chemical, photochemical process to inactivate or kill blood-borne pathogens. These can include methods based on solvent and detergent techniques, photochemical inactivation techniques, such as Mirasol® (Terumo BCT, Lakewood, CO, USA) and INTERCEPT® (Cerus Corporation, Concord, CA, USA), and others70. Some techniques focus on plasma for transfusion or specific blood components, while others are under assessment for whole blood pathogen reduction. Some PI technologies for blood products are already being implemented, while newer alternatives are currently under development. PI technologies are met with several different challenges and expectations. They are expected to inactivate enveloped and non-enveloped viruses, gram-negative and gram-positive bacteria, various different parasites and white blood cells while simultaneously not damaging the blood product or otherwise posing a threat to the recipient. Most PI technologies focus on targeting the nucleic acids of pathogens as RBC and platelets do not have a nucleus. However, there is a risk of damaging important blood membrane molecules and proteins, which can compromise the quality of the blood product71.
Solvent/Detergent
Solvent/Detergent (S/D) works to inactivate pathogens via membrane-disruption70. The typical S/D treatment, such as the one used for fractionated coagulation factors concentrates, involves a combination of an organic solvent, such as tri(n-butyl)phosphate (TNBP), and a non-ionic detergent (such as sodium cholate, Tween 80, Triton X-45 or Triton X-100) at 24 followed by removal of compounds via oil extraction and/or chromatography70,72. S/D techniques using TNBP and Triton-45 and applied to mini-pool or individual plasma donations have demonstrated efficacy in the inactivation of HCV and DENV in blood plasma73–75. Octaplas (Octapharma AG, Lachen, Switzerland) is an example of industrial-scale S/D-treated human plasma that replaces multiple coagulation factors in patients undergoing liver or heart transplant. Octaplas methodology can be applied for the treatment of either apheresis or whole blood derived-plasma. SDR HyperD® and C18 packings are chromatographic sorbents designed to remove solvent and detergent from blood products and other biological fluids after pathogen inactivation. Octapharma S/D technology was licensed for use in plasma in the United Kingdom in 1998 and as early as 1985 in other countries, and VIPS S/D technology received Conformité Européenne (CE) mark certification in 2009 and is licensed in Egypt76. It should be kept in mind that this process does not inactivate non-enveloped viruses, but was shown to affect some bacteria77.
THERAFLEX® MB-Plasma System
The THERAFLEX® (Macopharma, Mouvaux, France) pathogen reduction system incorporates filtration, methylene blue (MB) and 630 nm visible light for pathogen inactivation in single units of plasma3,78. This system differs from the technology used on platelets, which uses short-wave, or narrow-bandwidth UVC light and agitation to create pyrimidine dimers79. MB interacts with the nucleic acids. Because MB alone is ineffective against intracellular pathogens, plasma is additionally subject to filtration prior to treatment80. Fifteen countries currently use THERAFLEX® MB-Plasma technology78.
INTERCEPT® Blood System (Psoralen/UVA)
In the INTERCEPT® system, psoralen amotosalen is used in combination with UV light to penetrate the nucleus of pathogens and form non-covalent bonds between pyrimidic bases of DNA or RNA. UV light energy between 320–400 nm (UVA) transforms the non-covalent bond into a covalent bond preventing DNA from being replicated and blocking RNA from being transcribed. The INTERCEPT® Blood System can be used for the treatment of plasma and platelets, but potentially results in the loss of 10% of treated platelets. However, the efficacy of INTERCEPT® at treating platelets has been well documented. Although routinely used against bacteria, enveloped and non-enveloped viruses and protozoa, the INTERCEPT® Blood System is less effective against some viruses and ineffective against prions. As of July 2013, at least 20 countries have implemented the use of the INTERCEPT® Blood System, including several areas in Europe81,82. More specifically, 13 countries currently use the INTERCEPT® System to treat blood plasma and 22 countries use the INTERCEPT® Blood System to treat platelets78.
Mirasol® PRT system (Riboflavin/UV)
Mirasol® Pathogen Reduction Technology (PRT) is a treatment based on the application of riboflavin (RB), also called vitamin B2, followed by illumination with ultraviolet light (UV) with light energy in the range of 265–370 nm for approximately 5 minutes2,83. UV light can activate RB resulting in the formation of free oxygen radicals and selective destruction of the DNA and RNA of bacteria, viruses and other potential blood-borne pathogens81,84. It can also inactivate leucocytes with minimal damage to blood products84. Because RB is an essential nutrient in blood, and is regarded by regulatory authorities as a “GRAS” (generally regarded as safe) substance85, it has been thought that there is no need to remove it from the blood after the treatment2. Mirasol® PRT is effective in the treatment of plasma, platelets, RBC and whole blood, and has demonstrated the potential to reduce heavily harmful bacterial infections with up to 98% efficacy after transfusion86,87. A separate study conducted for the African Investigation of the Mirasol® System (AIMS), determined Mirasol® PRT was significantly effective at reducing transfusion-transmitted malaria in a hospital in sub-Saharan Africa88. This technology has been approved for use in Europe and several locations in the Middle East2,83. However, it has not yet been approved in the USA or for plasma and platelets. It has not been licensed anywhere for whole blood or RBC.
THERAFLEX® UV-C Technology
For pathogen inactivation, platelet concentrates are suspended in an additive solution and agitated to allow for increased mixing and higher penetration of UVC light3. The lack of photoactive chemicals reduces toxicological risks79. The THERAFLEX® system has demonstrated efficacy in the inactivation of bacteria, viruses and protozoa. THERAFLEX® UV-treated platelets are currently under phase 3 clinical trials; one concern is that HIV has been shown to be resistant to UVC light, which may be because HIV uses reverse transcriptase for replication and possibly its repair mechanism3.
Unfortunately, PITs are highly ineffective at removing vCJD disease from blood components89. Consequently, there are no licensed PITs for vCJD90. Currently, the most successful approach to reducing prions from blood products is by filtration. However, despite the aid of filtration, there are no effective testing procedures to determine residual prion infectivity levels beyond filtration91. It should be stressed that no PITs applied to blood components provide absolute guaranteed protection against all blood-borne pathogens, but, in the absence of large pooling, they do contribute substantially to their margin of safety.
Towards pathogen inactivation in RBC and whole blood
For pathogen inactivation in RBC or whole blood, there are two general approaches: 1) whole blood can be fractionated into its components and then PI processes can be applied to the RBC separated from the other components; 2) the PI treatment can be directly applied to the whole blood62. Early attempts were made in 2002 to virally-inactivate RBC using PEN 110 (INACTINE) by reacting with nucleic acids of pathogen DNA and RNA without light activation87,92. After successfully passing phase I and phase II trials, PEN 110 was halted due to antibody responses during the phase III trial93. Although it did not apparently harm erythrocytes, formations of antibodies against RBC did occur in patients receiving PEN 110-treated RBC87, eventually leading to its discontinuation93.
Mirasol®
Having already successfully proven its efficacy for pathogen inactivation in platelets and plasma, Mirasol® has recently been developed to treat whole blood70. The development and studies on the efficacy of Mirasol® technology had previously completed a phase III clinical trial for the inactivation of malaria in whole blood transfusion in Ghana. The phase III trial indicated clinically significant reduction of malaria in Mirasol®-treated blood samples compared to control on untreated whole blood, as well as a lower incidence of transfusion-related adverse events88. According to one report, Mirasol® technology has recently received CE approval for whole blood94.
Cerus S-303 INTERCEPT® (FRALE)
Designed by Cerus Corporation, the S-303 system was granted its CE mark in 200295. Rather than using UV light, the S-303 system applies a fully chemical approach by utilising the S-303 frangible anchor (mustard hydrochloride moiety) linker (alkyl chain) effector (acridine moiety), also known as the “FRALE” method, to form irreversible crosslinks in DNA, preventing replication and resulting in pathogen inactivation2,76,95. The compound S-300 and heteroalkyl compounds are generated as an end product of the S-303 reaction. This procedure incorporates the addition of glutathione to prevent protein damage in the process80. Although previous studies did not measure S-300 deposits in the body after transfusion treated with the S-303 FRALE system, it was believed that short-short term studies on toxicology will not reveal carcinogenicity or other genotoxic consequences95. A phase III trial on S-303 conducted over a decade ago demonstrated a significant increase in patients developing constipation. Also, 2 of the 148 subjects developed positive indirect antiglobulin tests96,97. This resulted in the S-303 development programme being halted80. However, Cerus recently developed a 2nd-generation treatment for RBC using 10 times more glutathione and an adjusted pH, and has recently started recruiting patients for its phase III clinical trial in Europe70,79,80. The application of S-303 FRALE toward pathogen inactivation in RBC does not appear to yield antibodies against red cells. However, there is a concern that S-303 FRALE might alkylate proteins, causing neoantigen formation after repeated treatments of patients87. More research is needed to determine adverse effects that may include genotoxicology, immunotoxicology and carcinogenicity95. Once concerns are addressed, S-303 PI technology has a potential to move toward commercialisation97.
With the exception of INTERCEPT® technologies and Octaplas S/D, the US Food and Drug Administration (FDA) have not approved most PITs in the USA due to concerns as to whether PIT can modify or degrade transfusion products80. To overcome restrictions from the USA, PITs must demonstrate safety as well as direct evidence of effective pathogen elimination. In Europe, most countries allow the implementation of PI technologies with pharmaceutical license or CE mark certification, depending upon the procedure used and pooling. So far, S/D, INTERCEPT®, Mirasol® and THERAFLEX® MB are approved for plasma and INTERCEPT®, Mirasol® and THERAFLEX® UVC have CE mark certification for platelets76,79,80 (Table I). The CE mark determines the readiness with which a particular technology can be introduced on the market79. The Mirasol® system received a CE mark class IIb, which requires self-certification by the manufacturer and INTERCEPT® (amotosalen) system received a CE mark class III, meaning that it requires the clinical data approved by a national authority79. In developing countries, blood screening in the presence or absence of PI technology already represents an economic challenge. Currently, many poorer areas are in need of an inexpensive alternative to existing PI technologies.
Table I.
Manufacturer | Technology | Key mechanisms | Transfusion components | Licensing | Countries |
---|---|---|---|---|---|
Cerus | INTERCEPT® | Amotosalen + UVA Light (320–400 nm) | Platelets (apheresis or whole blood-derived) | CE marked (class III) 2002 | 22 |
INTERCEPT® | Amotosalen + UVA Light (320–400 nm) | Plasma (apheresis or whole blood-derived) | CE marked (class III) 2006 | 13 | |
INTERCEPT® | S-303 (FRALE) | Red cells | n/a | - | |
INTERCEPT® | S-303 (FRALE) | Whole blood | n/a | - | |
| |||||
Terumo BCT | Mirasol® | Riboflavin + UVB Light (280–360 nm) | Platelets (apheresis or whole blood-derived) | CE marked (class IIB) 2007 | 18 |
Mirasol® | Riboflavin + UVB Light (280–360 nm) | Plasma (apheresis or whole blood-derived) | CE marked (class IIB) 2008 | 11 | |
Mirasol® | Riboflavin + UVB Light (280–360 nm) | Whole blood | CE marked 2015 | - | |
| |||||
Macopharma | THERAFLEX® | UVC light | Platelets | CE marked (class IIB) 2009 | - |
THERAFLEX® | Filtration + Methylene Blue + visible light (400–700 nm) | Fresh frozen plasma (apheresis or whole blood-derived) | CE marked (class III) 2004 | 15 | |
| |||||
Octapharma | Octaplas (S/D) | Solvent/Detergent | Large-pool of plasma (apheresis or whole blood-derived) | Licensed (in UK) 1998 | 32 |
| |||||
VIPS | n/a | Solvent/Detergent | Single donation or mini-pool of plasma (apheresis or whole blood-derived) | CE marked 2009 | At least 3 |
| |||||
Vitex | INACTINE | PEN 110 | Red cells | n/a | - |
n/a: not available; UVA/B/C: ultraviolet A/B/C.
Cost considerations
The impact of cost on PI technology implementation may dictate how much risk of product contamination certain countries are willing to accept78. The financial burden associated with some PI technologies may be considered an unaffordable luxury. Cost concerns with implementing PIT include, in addition to the purchase of equipment and kits, expenses to ensure training on proper maintenance, safe and proper usage as well as quality testing. An anticipated key limitation, for example, involves the cost of combining new technologies with current testing routines. This challenge would be a consequence of the longstanding traditional methods of testing that blood bank workers are accustomed to95. Opportunity cost may be a large factor in the decision-making process, taking into consideration that PIT may be used to inactivate rather than test for emerging infectious agents. It is important to note that the cost of opting to use PI technology may, therefore, reduce current expenses associated with donor screening procedures, risk-based decisions, and costs associated with treating TTI-affected patients. One report claims that the World Bank estimated that a $ 26 million public health investment could be enough to prevent 90% of Ebola cases in West Africa. A worthy challenge for researchers would be to merge all existing data investigating costs and risks to establish a model for acceptable risk. Missing the opportunity to do this led to expenses of $ 1.6 billion for emergency responses combating Ebola outbreaks in the region78. Although this particular instance was unrelated to transfusion, it serves as an indication of the potential increased expense related to the failure of investing in medical technology and knowledge directed at preventing the spread of disease.
Although PI technology is known to be expensive, there have been few studies that directly compare cost and benefit among the various PI technology options97.
Conclusions
Efforts to address the spread of frequent and serious transfusion-transmitted reactions of the 20th century have led to strict regulations and guidelines being put in place, resulting in a 1,000-fold decrease in the transfusion-transmission of infections such as HIV, HBV and HCV98. The associated risks for RBC and whole blood could be significantly further reduced with the approval of adequate PI technology. Before wide scale implementation of PI technology for RBC and whole blood, that technology must be proven to be safe, cost-effective, and efficient at inactivating pathogens2. Currently, clinical trials and policies dictating the application of PI technology may act as a barrier to the use of PI systems in some countries. The impact of global warming may have a very serious impact on the necessity to implement effective PI technology. As temperatures rise, the transmission of vector-borne pathogens may increase dramatically. This may lead to an increase in the transmission of diseases like WNV, DENV, ZIKV, CHIKV and others. As a direct consequence, the implementation of PI technology may be an increasingly attractive proposition97.
There have been tremendous advances made towards the safety of blood transfusion over the past few decades as a result of the technologies developed to target immunological and infectious risks. Many of the existing PI systems are easy to apply and take only a matter of minutes80. There has not yet been a consensus on the most effective practices in the treatment and management of blood among Blood Establishments, although conferences may promote future agreements99. Viral inactivation for plasma products is almost a universal standard, but as of today, there are still no universal PI technologies applicable to all transfusion products, although some are promising. Also, every current PI technology has difficulty dealing with spore-forming bacteria in platelet concentrates71. A separate challenge is that blood transfusions are regarded as expensive treatments among less wealthy countries80,99. Infrastructure would add to the investment challenge for developing countries intending to incorporate the newest PI technology80. Therefore, options that may be ideal for a wealthy country may not be as desirable for a lower income country. Cost is regarded as an important factor in determining the most preferred solution in blood treatment processes. An ideal PI system would be affordable for developing countries, effective at killing a wide range of pathogens, and have no toxicity or carcinogenicity76. Authorities on the topic of blood safety are tasked with finding a balance between affordable, effective PI technology and acceptable quality standards of blood products. Potential benefits of such a system include reducing the risk of current TTIs to zero, eliminating “blind spot” areas of modern testing procedures, and wiping out the need for donor screening questions62. The previous studies have been encouraging indicators of the significant progress in pathogen inactivation and reduced risk of whole blood products possible in the near future.
Footnotes
The Authors declare no conflicts of interest.
References
- 1.World Health Organization. 10 Facts on Blood Transfusion. 2016. [Accessed on 05/04/2017]. Available from: http://www.who.int/features/factfiles/blood_transfusion/en/
- 2.Picker SM. Pathogen Reduction Technologies: the best solution for safer blood? J Blood Disord Transfus. 2013;3:133. [Google Scholar]
- 3.Lozano M, Cid J. Platelet concentrates: Balancing between efficacy and safety? Presse Med. 2016;45:e289–98. doi: 10.1016/j.lpm.2016.06.020. [DOI] [PubMed] [Google Scholar]
- 4.Freimanis G, Sedegah M, Owusu-Ofori S, et al. Investigating the prevalence of transfusion transmission of Plasmodium within a hyperendemic blood donation system. Transfusion. 2013;53:1429–41. doi: 10.1111/j.1537-2995.2012.03943.x. [DOI] [PubMed] [Google Scholar]
- 5.World Health Organization. Annex 4: WHO guidelines on good manufacturing practices for blood establishments. 2011. [Accessed on 05/04/2017]. Available at: http://www.who.int/bloodproducts/publications/GMP_Bloodestablishments.pdf.
- 6.World Health Organization. Annex 4: WHO recommendations for the production, control and regulation of human plasma for fractionation. 2005. [Accessed on 05/04/2017]. Available at: http://www.who.int/biologicals/publications/ECBS2005Annex4HumanPlasmaFractionation.pdf.
- 7.Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016;22:839–50. doi: 10.1038/nm.4108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Kanki PJ, Hamel DJ, Sankalé J-L, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999;179:68–73. doi: 10.1086/314557. [DOI] [PubMed] [Google Scholar]
- 9.Dhingra N. Making safe blood available in Africa. 2006. [Accessed on 05/04/2017]. Available at: http://www.who.int/bloodsafety/makingsafebloodavailableinafricastatement.pdf.
- 10.Bruisten S, Van Gemen B, Koppelman M, et al. Detection of HIV-1 distribution in different blood fractions by two nucleic acid amplification assays. AIDS research and human retroviruses. 1993;9:259–65. doi: 10.1089/aid.1993.9.259. [DOI] [PubMed] [Google Scholar]
- 11.Lee T, Stromberg R, Heitman J, et al. Distribution of HIV type 1 (HIV-1) in blood components: detection and significance of high levels of HIV-1 associated with platelets. Transfusion. 1998;38:580–8. doi: 10.1046/j.1537-2995.1998.38698326338.x. [DOI] [PubMed] [Google Scholar]
- 12.Ott J, Stevens G, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9. doi: 10.1016/j.vaccine.2011.12.116. [DOI] [PubMed] [Google Scholar]
- 13.World Health Organization. Fact sheet: Hepatitis B. 2016. [Accessed on 05/04/2017]. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/
- 14.Seo DH, Whang DH, Song EY, et al. Occult hepatitis B virus infection and blood transfusion. World J Hepatol. 2015;7:600. doi: 10.4254/wjh.v7.i3.600. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.World Health Organization. Fact sheet: Blood safety and availability. 2016. [Accessed on 05/04/2017]. Available at: http://www.who.int/mediacentre/factsheets/fs279/en/
- 16.Australian Red Cross Blood Service. 2015 Surveillance Report: Transfusion-transmissible infections in Australia. 2015. [Accessed on 05/04/2017]. Available at: https://kirby.unsw.edu.au/sites/default/files/hiv/resources/tti2015_20160226.pdf.
- 17.Seed C, Maloney R, Kiely P, et al. Infectivity of blood components from donors with occult hepatitis B infection-results from an Australian lookback programme. Vox sanguinis. 2015;108:113–22. doi: 10.1111/vox.12198. [DOI] [PubMed] [Google Scholar]
- 18.Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. Journal of General Virology. 2004;85:3173–88. doi: 10.1099/vir.0.80401-0. [DOI] [PubMed] [Google Scholar]
- 19.Moreno M, Pérez-Alvarez R, Rodrigo L, et al. Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response. Journal of viral hepatitis. 2006;13:28–33. doi: 10.1111/j.1365-2893.2005.00650.x. [DOI] [PubMed] [Google Scholar]
- 20.Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. doi: 10.1002/hep.26141. [DOI] [PubMed] [Google Scholar]
- 21.Thong VD, Akkarathamrongsin S, Poovorawan K, et al. Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication. WJG. 2014;20:2927. doi: 10.3748/wjg.v20.i11.2927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Chao D, Abe K, Nguyen M. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Alimentary pharmacology & therapeutics. 2011;34:286–96. doi: 10.1111/j.1365-2036.2011.04714.x. [DOI] [PubMed] [Google Scholar]
- 23.Well E, First F, it Out W, et al. Study identifies hepatitis C virus genotype 1 as the most prevalent worldwide. Nursing Standard. 2014;50:17. [Google Scholar]
- 24.Centers for Dis ease Control and Prevention. Hepatitis C FAQs for the public. 2016. [Accessed on 05/04/2017]. Available at: http://www.cdc.gov/hepatitis/hcv/cfaq.htm.
- 25.Padovani JL, Corvino SM, Drexler JF, et al. In vitro detection of hepatitis C virus in platelets from uninfected individuals exposed to the virus. Revista da Sociedade Brasileira de Medicina Tropical. 2013;46:154–5. doi: 10.1590/0037-8682-1627-2013. [DOI] [PubMed] [Google Scholar]
- 26.Amer A, Abu Madi M, Shebl F, et al. Platelets as a possible reservoir of HCV and predictor of response to treatment. J Virol Antivir Res. 2016;5:3. [Google Scholar]
- 27.Schmidt WN, Wu P, Han J-Q, et al. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load. J Infect Dis. 1997;176:20–6. doi: 10.1086/514024. [DOI] [PubMed] [Google Scholar]
- 28.Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant. 2011;11:1188–200. doi: 10.1111/j.1600-6143.2011.03460.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Rios M, Daniel S, Chancey C, et al. West Nile virus adheres to human red blood cells in whole blood. Clin Infect Dis. 2007;45:181–6. doi: 10.1086/518850. [DOI] [PubMed] [Google Scholar]
- 30.Davis LE, DeBiasi R, Goade DE, et al. West Nile virus neuroinvasive disease. Ann Neurol. 2006;60:286–300. doi: 10.1002/ana.20959. [DOI] [PubMed] [Google Scholar]
- 31.Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet. 2001;358:261–4. doi: 10.1016/S0140-6736(01)05480-0. [DOI] [PubMed] [Google Scholar]
- 32.Harrington T, Kuehnert MJ, Kamel H, et al. West Nile virus infection transmitted by blood transfusion. Transfusion. 2003;43:1018–22. doi: 10.1046/j.1537-2995.2003.00481.x. [DOI] [PubMed] [Google Scholar]
- 33.García G, González N, Pérez AB, et al. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis. 2011;15:e38–43. doi: 10.1016/j.ijid.2010.09.008. [DOI] [PubMed] [Google Scholar]
- 34.Endy TP, Chunsuttiwat S, Nisalak A, et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol. 2002;156:40–51. doi: 10.1093/aje/kwf005. [DOI] [PubMed] [Google Scholar]
- 35.Wang S, He R, Patarapotikul J, et al. Antibody-enhanced binding of dengue-2 virus to human platelets. Virology. 1995;213:254–7. doi: 10.1006/viro.1995.1567. [DOI] [PubMed] [Google Scholar]
- 36.Wang W-K, Sung T-L, Tsai Y-C, et al. Detection of dengue virus replication in peripheral blood mononuclear cells from dengue virus type 2-infected patients by a reverse transcription-real-time PCR assay. J Clin Microbiol. 2002;40:4472–8. doi: 10.1128/JCM.40.12.4472-4478.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Liumbruno GM, Calteri D, Petropulacos K, et al. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus. 2008;6:199–210. doi: 10.2450/2008.0016-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Parola P, De Lamballerie X, Jourdan J, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis. 2006;12:1493–9. doi: 10.3201/eid1210.060610. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Di Minno G, Perno CF, Tiede A, et al. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Rev. 2016;30:35–48. doi: 10.1016/j.blre.2015.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Mittal A, Mittal S, Bharathi JM, et al. Uveitis during outbreak of Chikungunya fever. Ophthalmology. 2007;114:1798. doi: 10.1016/j.ophtha.2007.03.045. [DOI] [PubMed] [Google Scholar]
- 41.Mittal A, Mittal S, Bharati MJ, et al. Optic neuritis associated with chikungunya virus infection in South India. Arch Ophthalmol. 2007;125:1381–6. doi: 10.1001/archopht.125.10.1381. [DOI] [PubMed] [Google Scholar]
- 42.Mlakar J, Korva M, Tul N, et al. Zika virus associated with microcephaly. New Engl J Med. 2016;374:951–8. doi: 10.1056/NEJMoa1600651. [DOI] [PubMed] [Google Scholar]
- 43.World Health Organization. Fact sheet: Zika. 2016. [Accessed on 05/04/2017]. Available at: http://www.who.int/mediacentre/factsheets/zika/en/
- 44.Brasil P, Pereira J, Jose P, Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro - preliminary report. New Engl J Med. 2016;375:2321–34. doi: 10.1056/NEJMoa1602412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Corsica F. Zika virus transmission from French Polynesia to Brazil. Emerg Infect Dis. 2015;21:1887. doi: 10.3201/eid2110.151125. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Centers for Dis ease Control and Prevention. Zika and blood transfusion. 2016. [Accessed on 05/04/2017]. Available at: http://www.cdc.gov/zika/transmission/blood-transfusion.html.
- 47.Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. New Engl J Med. 2016;375:1101–3. doi: 10.1056/NEJMc1607262. [DOI] [PubMed] [Google Scholar]
- 48.Food & Drug Administration. FDA advises testing for Zika virus in all donated blood and blood components in the US. 2016. [Accessed on 05/04/2017]. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518218.htm.
- 49.Cohen SE, Klausner JD, Engelman J, et al. Syphilis in the modern era: an update for physicians. Infect Dis Clin North Am. 2013;27:705–22. doi: 10.1016/j.idc.2013.08.005. [DOI] [PubMed] [Google Scholar]
- 50.Schmidt PJ. Syphilis, a disease of direct transfusion. Transfusion. 2001;41:1069–71. doi: 10.1046/j.1537-2995.2001.41081069.x. [DOI] [PubMed] [Google Scholar]
- 51.Bowen V, Su J, Torrone E, et al. Increase in incidence of congenital syphilis - United States, 2012–2014. MMWR Morb Mortal Wkly Rep. 2015;64:1241–5. doi: 10.15585/mmwr.mm6444a3. [DOI] [PubMed] [Google Scholar]
- 52.De Santis M, De Luca C, Mappa I, et al. Syphilis infection during pregnancy: fetal risks and clinical management. Infect Dis Obstet Gynecol. 2012;2012:430585. doi: 10.1155/2012/430585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Owusu-Ofori AK, Parry CM, Bates I. Transfusion-transmitted syphilis in teaching hospital, Ghana. Emerg Infect Dis. 2011;17:2080–2. doi: 10.3201/eid1711.110985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Bisseye C, Sanou M, Nagalo BM, et al. Epidemiology of syphilis in regional blood transfusion centres in Burkina Faso, West Africa. Pan Afr Med J. 2013;16:69. doi: 10.11604/pamj.2013.16.69.2767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Angchaisuksiri P. Coagulopathy in malaria. Thromb Res. 2014;133:5–9. doi: 10.1016/j.thromres.2013.09.030. [DOI] [PubMed] [Google Scholar]
- 56.World Health Organization. Fact sheet: Malaria. 2016. [Accessed on 05/04/2017]. Available at: http://www.who.int/mediacentre/factsheets/fs094/en/
- 57.Tusting LS, Bousema T, Smith DL, et al. Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol. 2014;84:151. doi: 10.1016/B978-0-12-800099-1.00003-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Kitchen A, Chiodini P. Malaria and blood transfusion. Vox Sang. 2006;90:77–84. doi: 10.1111/j.1423-0410.2006.00733.x. [DOI] [PubMed] [Google Scholar]
- 59.del Prado GRL, García CH, Cea LM, et al. Malaria in developing countries. J Infect Develop Count. 2014;8:1–4. doi: 10.3855/jidc.4610. [DOI] [PubMed] [Google Scholar]
- 60.Kleinschmidt I, Schwabe C, Benavente L, et al. Marked increase in child survival after four years of intensive malaria control. Am J Trop Med Hyg. 2009;80:882–8. [PMC free article] [PubMed] [Google Scholar]
- 61.Milner D, Daily J, Baron EL. Pathogenesis of malaria. UpToDate. 2012. [Accessed on 05/04/2017]. Available at: www.uptodate.com.
- 62.Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion. 2015;55:2983–3000. doi: 10.1111/trf.13259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Urwin P, Mackenzie J, Llewelyn C, et al. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang. 2016;110:310–6. doi: 10.1111/vox.12371. [DOI] [PubMed] [Google Scholar]
- 64.Neisser-Svae A, Seghatchian J. The state of the art of removal of prion proteins in SD-FFP, by specific prion affinity chromatography and its impact on the hemostatic characteristics of the product. Transfus Aphs Sci. 2015;52:237–9. doi: 10.1016/j.transci.2015.02.012. [DOI] [PubMed] [Google Scholar]
- 65.Centers for Dis ease Control and Prevention. Diseases and organisms: blood safety. 2013. [Accessed on 05/04/2017]. Available at: http://www.cdc.gov/bloodsafety/bbp/diseases_organisms.html.
- 66.Chatterjee K, Zaman S, Chaurasia R, et al. Evaluation of Mirasol pathogen reduction system by artificially contaminating platelet concentrates with Staphylococcus epidermidis: a pilot study from India. Asian Journal of Transfusion Science. 2016;10:127. doi: 10.4103/0973-6247.187946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Hoad VC, Speers DJ, Keller AJ, et al. First reported case of transfusion-transmitted Ross River virus infection. Med J Aust. 2015;202:267–70. doi: 10.5694/mja14.01522. [DOI] [PubMed] [Google Scholar]
- 68.Dodd RY. Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Brit J Haematol. 2012;159:135–42. doi: 10.1111/bjh.12031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Burnouf T. Modern plasma fractionation. Transfus Med Rev. 2007;21:101–17. doi: 10.1016/j.tmrv.2006.11.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Chen L, Yao M. Pathogen inactivation plays an irreplaceable role in safeguarding the safety of blood transfusion. J Antivir Antiretrovir. 2016;8:LXXIII–LXXIV. [Google Scholar]
- 71.Mundt JM, Rouse L, Van den Bossche J, et al. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol. 2014;90:957–64. doi: 10.1111/php.12311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826–31. [PubMed] [Google Scholar]
- 73.Chou M-L, Burnouf T, Chang S-P, et al. TnBP/Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. PloS one. 2015;10:e0117800. doi: 10.1371/journal.pone.0117800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.El-Ekiaby M, Sayed M, Caron C, et al. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transf Med. 2010;20:48–61. doi: 10.1111/j.1365-3148.2009.00963.x. [DOI] [PubMed] [Google Scholar]
- 75.Burnouf T, Chou ML, Cheng LH, et al. Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate. Vox Sang. 2013;104:1–6. doi: 10.1111/j.1423-0410.2012.01621.x. [DOI] [PubMed] [Google Scholar]
- 76.Prowse C. Component pathogen inactivation: a critical review. Vox Sang. 2013;104:183–99. doi: 10.1111/j.1423-0410.2012.01662.x. [DOI] [PubMed] [Google Scholar]
- 77.Chou ML, Wu YW, Su CY, et al. Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. Vox Sang. 2012;102:277–84. doi: 10.1111/j.1423-0410.2011.01560.x. [DOI] [PubMed] [Google Scholar]
- 78.Walsh GM, Shih AW, Solh Z, et al. Blood-Borne pathogens: a Canadian blood services centre for innovation symposium. Transfus Med Rev. 2016;30:53–68. doi: 10.1016/j.tmrv.2016.02.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother. 2014;41:309–25. doi: 10.1159/000365646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Salunkhe V, van der Meer PF, de Korte D, et al. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands. Transfus Aph Sci. 2015;52:19–34. doi: 10.1016/j.transci.2014.12.016. [DOI] [PubMed] [Google Scholar]
- 81.Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev. 2014;28:235–41. doi: 10.1016/j.blre.2014.07.005. [DOI] [PubMed] [Google Scholar]
- 82.Castiglia S, Mareschi K, Labanca L, et al. Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in good manufacturing practice conditions. Cytotherapy. 2014;16:750–63. doi: 10.1016/j.jcyt.2013.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Tormey CA, Santhanakrishnan M, Smith NH, et al. Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion. 2016;56:863–72. doi: 10.1111/trf.13432. [DOI] [PubMed] [Google Scholar]
- 84.Pinto JT, Zempleni J. Riboflavin. Adv Nutr. 2016;7:973–5. doi: 10.3945/an.116.012716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Food & Drug Administration. Select Committee on GRAS Substances (SCOGS) Opinion: Riboflavin, Riboflavin-5′-phosphate. 2015. [Accessed on 05/04/2017]. Available at: https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm261091.htm.
- 86.Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion. 2009;49:1205–16. doi: 10.1111/j.1537-2995.2009.02126.x. [DOI] [PubMed] [Google Scholar]
- 87.Sobral PM, Barros AEdL, Gomes AMAS, et al. Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids. Rev Bras Hematol Hemoter. 2012;34:231–5. doi: 10.5581/1516-8484.20120056. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Allain J-P, Owusu-Ofori AK, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet. 2016;387:1753–61. doi: 10.1016/S0140-6736(16)00581-X. [DOI] [PubMed] [Google Scholar]
- 89.Seghatchian J. Multilayer-strategy to enhance optimal safety of the blood supply: the role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: moderator views. Transfus Apher Sci. 2015;52:233–6. doi: 10.1016/j.transci.2015.02.011. [DOI] [PubMed] [Google Scholar]
- 90.Wiltshire M, Meli A, Schott M, et al. Quality of red cells after combination of prion reduction and treatment with the intercept system for pathogen inactivation. Transfus Med. 2016;26:208–14. doi: 10.1111/tme.12298. [DOI] [PubMed] [Google Scholar]
- 91.de Sousa G, Seghatchian J. Highlights of PBTI coimbra conference on PRT of plasma & current opinions on pathogen reduction treatment of blood components. Transfus Apher Sci. 2015;52:228–32. doi: 10.1016/j.transci.2015.02.010. [DOI] [PubMed] [Google Scholar]
- 92.AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion. 2002;42:146–52. doi: 10.1046/j.1537-2995.2002.00021.x. [DOI] [PubMed] [Google Scholar]
- 93.Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci. 2008;39:75–82. doi: 10.1016/j.transci.2008.05.003. [DOI] [PubMed] [Google Scholar]
- 94.Kwon SY. Pathogen reduction technology - is it time? ISBT Sci Ser. 2016;11:117–22. [Google Scholar]
- 95.Nkohkwo Aa, Agbor G, Asongalem E, et al. Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: a systematic review with regional discussion. Afr J Lab Med. 2016;5:a363. doi: 10.4102/ajlm.v5i1.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion. 2005;45:1739–49. doi: 10.1111/j.1537-2995.2005.00583.x. [DOI] [PubMed] [Google Scholar]
- 97.Marks D, Faddy H, Johnson L. Pathogen reduction technologies. ISBT Sci Ser. 2014;9:44–50. [Google Scholar]
- 98.Seghatchian J, Putter JS. Pathogen inactivation of whole blood and red cell components: an overview of concept, design, developments, criteria of acceptability and storage lesion. Transfus Apher Sci. 2013;49:357–63. doi: 10.1016/j.transci.2013.07.023. [DOI] [PubMed] [Google Scholar]
- 99.Garraud O, Cognasse F, Tissot J-D, et al. Improving platelet transfusion safety: biomedical and technical considerations. Blood Transfus. 2016;14:109. doi: 10.2450/2015.0042-15. [DOI] [PMC free article] [PubMed] [Google Scholar]